Since we had proved that LN+ patients had a higher StrLNM signature score, we believed AZGP1, C11orf86, HSD17B2 as well as SHH were potentially important biomarker candidates that were significantly associated with LNM and would contribute to the prediction of BLCA patients. This evidence concerns the gene C11orf86 and bladder transitional cell carcinoma.